news.google last weeks headlines / Matthew Pfeffer positive

[thekindaguyiyam]

US FDA advisers back MannKind's inhaled diabetes drug - CNBC.com
www.cnbc.com/id/101547157‎
CNBC
4 days ago - U.S. health advisers recommended approval of MannKind's inhaled diabetes ... Watch Mannkind CFO Matthew J. Pfeffer on CNBC's "Power Lunch" at 1 p.m. ET.
FDA panel backs Mannkind's 'Afrezza' - CNBC
video.cnbc.com/gallery/?video=3000263490‎
CNBC
4 days ago - Matthew Pfeffer, MannKind CFO, discusses the recommendation of an FDA panel to approve his company's inhaled insulin treatment "Afrezza."
MannKind Wins U.S. Panel Backing for Its Inhaled Insulin - Bloomberg
www.bloomberg.com/.../mannkind-wins-u-s-panel-backi...‎
Bloomberg L.P.
5 days ago - MannKind is in talks with “multiple companies” to find a partner, Matthew Pfeffer, the chief financial officer, said in a telephone interview before the panel meeting ...
MannKind Corporation's Investigational Drug to Treat Diabetes
www.news.mannkindcorp.com/phoenix.zhtml?...‎
MannKind Corporation
5 days ago - CONTACTS: Investors: Matthew J. Pfeffer Chief Financial Officer MannKind Corporation [e-mail] [phone] Media: Laura de Zutter ...
FDA panel backs Mannkind's 'Afrezza' - Video on NBCNews.com
►►
www.nbcnews.com/video/.../54847710NBCNews.com
4 days ago
Video on NBCNews.com: Matthew Pfeffer, MannKind CFO, discusses the recommendation of an FDA panel ...
FDA Advisory Committee Recommends Approval of AFREZZA(R ...
globenewswire.com/.../FDA-Advisory-Committee-Recom...‎
GlobeNewswire
5 days ago - April 01, 2014 17:47 | Source: MannKind Corporation ... Investors: Matthew J. Pfeffer Chief Financial Officer MannKind Corporation [phone] Media: Laura ...
FDA panel backs Mannkind's 'Afrezza' | Watch the video - Yahoo ...
finance.yahoo.com/.../fda-panel-backs-mannkinds...‎
Yahoo! Finance
4 days ago - Watch the video FDA panel backs Mannkind's 'Afrezza' on Yahoo Finance . Matthew Pfeffer, MannKind CFO, discusses the recommendation of an FDA panel to ...
Mannkind's inhaled insulin clears big hurdle - NewsTimes
www.newstimes.com/.../Mannkind-s-inhaled-insulin-cle...‎
The News‑Times
4 days ago - Danbury-based MannKind's hopes for Afrezza, an inhaled diabetes drug, took a ... with "multiple companies" to find a partner, Matthew Pfeffer, MannKind's chief ...
MannKind Stock Soars in Response to FDA Vote | San Fernando ...
www.sfvbj.com/news/2014/.../mannkind-stock-soars-response-fda-vote/‎
4 days ago - We think we're on the right path toward getting this to market,” MannKind's Chief Financial Officer Matthew J. Pfeffer told the Business Journal Wednesday.
FDA panel gives thumbs-up to Santa Clarita's MannKind
www.signalscv.com/section/36/.../117362/The Santa Clarita Valley Signal
5 days ago - FDA panel gives thumbs-up to Santa Clarita's MannKind ... would immediately go into commercial production, said Chief Financial Officer Matthew Pfeffer.

[thekindaguyiyam]

from the other board: posted by fullshred_2000

MUST READ recent quotes from Matthew Pfeffer
-If approved, the biopharmaceutical company’s revolutionary product is the first to deliver a rapid-acting, inhaled insulin powder for adults with Type 1 and Type 2 diabetes that goes right into the bloodstream within minutes.

-The target date for the FDA to complete its review is April 15.

-If MannKind gets the all clear signal from the FDA, Afrezza will immediately go into commercial production, said its Chief Financial Officer, Matthew Pfeffer.

-The FDA will require that the company produce a couple qualification lots first to ensure the process is capable of delivering quality product on a full scale commercial basis.

-But MannKind will ramp up production at its Danbury, CT facility to build up a good supply of the Afrezza, Pfeffer said.

-“We want to build up a good supply of product in advance of the launch,” he said. “We don’t want to run out.”

-The company has already tripled its manufacturing capacity, Pfeffer said.

-While a FDA decision is expected by April 15, that date is not a given. The FDA could ask for more time, but as of March 24 Pfeffer says MannKind has “not been notified yet of any delay.”

-A lot is riding on a green light from the FDA. If Afrezza’s inhalation device is approved, the technology lends itself to other projects that MannKind has in the pipeline.

-“One is a pain product,” Peffer said. “It’s in a very early stage, but it lends itself to our technology to get something into the bloodstream very, very quickly to provide fast pain relief.”

-But, more importantly, FDA approval would give the company the cash and chance to go after other applications.

-In other words, the method of delivering medications directly into the bloodstream through an inhalation device could take off.

-“This is the obvious direction, the one we have the most experience in,” Pfeffer said.

-If approved, the next step is for MannKind to partner with a large worldwide pharmaceutical company that already has marketing and distribution infrastructure in place.

-MannKind is confident in its product or it wouldn’t have made the application for the FDA review otherwise, he said."

[biotec]

This is all old info yam, nothing new.

[thekindaguyiyam]

It's obvious to me that you know much more than I do.
However I still enjoyed reading "as of March 24 Pfeffer says MannKind has “not been notified yet of any delay.”   

And did you not give your opinion "Well many are talking about the possibillity of a delay from the FDA, I heard everything from 2 weeks to 6 months."

Listen.  I think we got off to a bad start because of my misinterpreting something you said.  Can we let it go?  With that said; Of course I'd prefer continued fluidity and this coming off as planned in a timely way.
There is that possibility; everything else opinion.  As you said; we are all entitled to one.



Iyam